Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth? by Klopp, Ann H et al.
TISSUE-SPECIFIC STEM CELLS
Concise Review: Dissecting a Discrepancy in the Literature: Do
Mesenchymal Stem Cells Support or Suppress Tumor Growth?
ANN H. KLOPP,
a ANSHUL GUPTA,
a ERIKA SPAETH,
b MICHAEL ANDREEFF,
b FRANK MARINI, III
b
aDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas,
USA;
bDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Key Words. Mesenchymal stem cells • Adipose stem cells • Cancer • Stroma • Microenviroment
ABSTRACT
The discovery that mesenchymal stem cells (MSCs) are
recruited into tumors has led to a great deal of interest
over the past decade in the function of MSCs in tumors.
To address this, investigators have used a variety of tumor
models in which MSCs are added exogenously to deter-
mine their impact on tumor development. Interestingly,
many studies have reported contradicting results, with
some investigators ﬁnding that MSCs promote tumor
growth and others reporting that MSCs inhibit tumor
growth. Many mechanisms have been reported to account
for these observations, such as chemokine signaling, modu-
lation of apoptosis, vascular support, and immune modula-
tion. In this review, we analyzed the differences in the
methodology of the studies reported and found that the
timing of MSC introduction into tumors may be a critical
element. Understanding the conditions in which MSCs
enhance tumor growth and metastasis is crucial, both to
safely develop MSCs as a therapeutic tool and to advance
our understanding of the role of tumor stroma in carcino-
genesis. STEM CELLS 2011;29:11–19
Disclosure of potential conﬂicts of interest is found at the end of this article.
INTRODUCTION
Mesenchymal stem cells or multipotent mesenchymal stromal
cells (MSCs) are multipotent progenitor cells that exhibit a
marked tropism for tumors. MSCs form a tumor’s ﬁbrovascu-
lar network, differentiating into tumor-associated ﬁbroblasts
(TAFs) and vascular pericytes [1–3]. Despite extensive inves-
tigations over the past 5 years, the impact of unmodiﬁed
MSCs on tumor progression remains unclear. Many studies
have shown that MSCs promote tumor progression and metas-
tasis while other studies report that MSCs suppress tumor
growth (referenced in Tables 1 and 2). The reason for this
discrepancy is unknown, but it may be attributable to differ-
ences in tumor models, the heterogeneity of MSCs, the dose
or timing of the MSCs injected, the animal host, or another
factor that is not yet appreciated.
The tropism of MSC for tumors makes MSCs uniquely
destined to function as cellular delivery vehicles for antitumor
agents [27–32]. MSCs can deliver a diverse array of agents,
including interferon (IFN)-b, cytosine deaminase, tumor ne-
crosis factor-related apoptosis-inducing ligand, and oncolytic
viruses. These approaches have been explored in preclinical
cancer models and yielded potent antitumor effects [29–35].
Tumor-targeted production of antitumor agents is likely to
overcome any endogenous tumor-promoting effects of MSCs.
However, it is important to determine under what conditions
MSCs enhance tumor growth and metastasis to develop thera-
peutic applications and to understand the role of stroma in tu-
morigenesis. This review article focuses on studies that
directly investigated the effects of MSCs on tumors in vivo
and attempts to shed light on the contradictions reported in
the literature.
Isolation of MSCs
MSCs have been isolated from many types of adult and fetal
tissues using similar methodologies [36]. Bone marrow and
adipose tissues are rich sources of MSCs [37, 38]. MSCs
have also been isolated from many other adult tissues, includ-
ing kidney, skin, and the parathyroid gland [38–40]. MSCs or
MSC-like cells have also been isolated from fetal tissues,
including the skin, umbilical cord, and placenta [33, 41–43].
These tissue-derived MSCs share a number of important
characteristics with bone marrow-derived MSCs, including
cell surface marker expression, plastic adherence, and the
capacity to differentiate into cells of mesenchymal lineage
(i.e., fat, bone, muscle, and cartilage) under appropriate condi-
tions [37]. In addition, MSCs demonstrate a tumor tropism
that distinguishes them from other mesenchymal cells, such as
differentiated ﬁbroblasts [31, 44]. However, tissue-derived
MSCs are likely to differ in critical ways from the well-stud-
ied bone marrow-derived MSCs. It is possible that the contra-
dictions in study ﬁndings are attributable to the variability in
MSCs from different sources (i.e., bone marrow-derived
MSCs vs. tissue-derived MSCs) and variability in MSCs from
donor to donor even when obtained from the same source
using the same technique.
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MSCs are thought to endogenously support wound healing and
hematopoiesis, but many of the native functions of MSCs remain
poorly understood. When engrafted at sites of tissue injury,
MSCs differentiate into connective tissue elements, support vas-
culogenesis, and secrete cytokines and growth factors that facili-
tate healing. The potential of MSCs to promote tissue repair is
being investigated in a diverse array of diseases, including ische-
mic heart disease, diabetes, and Parkinson’s disease [45].
The function of MSCs in tumors is likely to parallel the role
of MSCs in wound healing. As in wounds, MSCs differentiate
in tumors into ﬁbroblasts and pericytes and, perhaps, endothe-
lial-like or vessel-attached cells [3, 46]. Additionally, MSCs
secrete a number matrix proteins and cytokines that can
increase proliferation and support vasculogenesis, such as vas-
cular endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF) [47].
MSCs also have complex immunomodulatory effects. MSCs
can counteract inﬂammation, by suppressing host immune
responses and preventing ﬁbrosis. The immunosuppressive prop-
erties of MSCs are being exploited in an effort to reduce the tox-
icity of allogeneic bone marrow transplant due to graft versus
host disease (GvHD) in which the transplanted cells formulate
an immune response against the transplant recipient [48, 49].
IMPACT OF MSC ON IN VIVO TUMORS
MSC Promotion of Tumor Growth
Studies reporting that MSCs can promote tumor growth are
listed in Table 1. Karnoub et al. [4] coinjected bone marrow-
derived human MSCs with green ﬂuorescent protein-labeled
human breast cancer cells (MCF/Ras, MDA-MB-231, MDA-
MB-435, and HMLER) in a ratio of 3:1 into immunocompro-
mised mice. The MSCs accelerated tumor growth in one of
the four cell lines (MCF/Ras) but did not affect local tumor
growth in the other cell types. Coinjection with MSCs
increased the number of breast cancer metastases that formed
in all cell lines investigated.
Bone marrow-derived MSCs have been shown to increase
the in vivo growth of colon cancer, lymphoma, and melanoma
cells [5, 6, 50]. Adult- and fetal-derived MSCs were coin-
jected with colon cancer cells (SW480 and F6) in a murine
xenograft model [5], resulting in an increased incidence of
tumors with enhanced vascularity and necrosis. Both adult
and fetal MSCs had similar growth-promoting effects, but
adult MSCs appeared to favor tumor incidence more than fe-
tal MSCs.
B16 melanoma cells transplanted into allogeneic mice did
not form tumors unless MSCs were coinjected [6]. This ﬁnd-
ing suggests MSCs have immunosuppressive effects, which
were required for tumor initiation in this model. MSCs also
support the in vitro survival of follicular lymphoma B cells
derived from human tumors. This protective effect of MSCs
was augmented further by treating MSCs with tumor necrosis
factor-a and lymphotoxin-a1b2 [50].
Adipose tissue is a rich source of multipotent MSCs
(referred to as adipose stem cells [ASCs]), which exhibit tu-
mor tropism and are thought to be functionally similar to
bone marrow-derived MSCs [40]. Muehlberg et al. [8] dem-
onstrated that ASCs can promote tumor growth in a syngeneic
mouse model. Mammary breast cancer cells were cotrans-
planted with ASCs, resulting in the development of larger and
Table 1. Studies reporting that MSC promote tumor growth
Author Isolation Tumor model
MSC:Tumor
cell ratio Findings Proposed mechanism
Karnoub et al. [4] Human
BMD-MSC
Breast (MCF/Ras,
MDA-MB-231,
MDA-MB-435,
and HMLER)
3:1 coinjected Increased size in one
cell line (MCF/
Ras) and increased
metastasis
Chemokine secretion
(CCL5)
Zhu et al. [5] Fetal and adult
BMD-MSCs
Colon cancer cell line
(SW480 and F6)
10:1, 1:1 coinjected Increased incidence Enhanced
proliferation and
angiogenesis
Djouad et al. [6, 7] Mouse BMD-MSC Melanoma (B16) 1:1 coinjected Increased incidence Immunologic
Muehlberg et al. [8] Human and
mouse ASCs
Breast (4T1 and
MDA231)
10:1 coinjected or
i.v. 24 hours later
Increased size Paracrine factor
(SDF-1/CXCR
secretion)
Yu et al. [9] Human ASC Lung or glioma
(H460 or U87MG)
1:1, 2:1, 1:10
coinjected
Increased size Reduced apoptosis
Galie et al. [10] Mouse ASC Breast (BB1) 1:1 Increased incidence
and size
Vasculogenic
Lin et al. [11] Human ASC Prostate (PC3) 1:2 injected in
contralateral
ﬂank after 7 days
Increased incidence
and size
Vasculogenic and
modulation of
tumoral CXCR4
Kucerova et. al. [12] Human ASC Melanoma (A375
and M4Beu) and
glioblastoma
multiforme
(8MGBA)
1:10-1:5 coinjected
or i.v. synchronous
with tumor
injections
Decreased latency
and increased size
of melanoma
xenografts
VEGF and SDF-
1a/CXCR4
Prantl et. al. [13] Human ASC Prostate 1:10 coinjection
subcutaneously
Increased size Vasculogenic with
differentiation into
endothelial cells
Shinagawa et al. [14] Human MSC Colon (KM12SM) 1:2 Coinjected into
cecum
Increased size and
metastasis
Increased
angiogenesis and
reduced apoptosis.
Abbreviations: ASC, adipose stem cell; BMD, bone-marrow derived; CCL5, chemokine ligand 5; CXCR4, C-X-C chemokine receptor type
4; i.v., intravenous delivery; MSC, mesenchymal stem cell; SDF, stromal-derived factor; VEGF, vascular endothelial growth factor.
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been shown to favor tumor cell growth in nude mice. When
human ASCs were coinjected subcutaneously with lung can-
cer or glioma cells (H460 or U87MG) into nude mice, there
was a substantial increase in the tumor size and the number
of viable tumor cells [9]. Lung cancer and Kaposi sarcoma
xenografts were promoted by injection of white adipose tissue
adjacent to tumor xenografts [52]. Adipose tissue-derived
stromal cells were detected within these xenograft tumors,
demonstrating that adipose stromal cells promote tumor
growth when recruited from regional adipose tissue.
However, in most of these reports MSCs were added to
ﬁxed numbers of tumor cells, resulting in increased total num-
bers of cells injected including both tumor cells and MSCs.
We have demonstrated earlier that MSCs proliferate in the
presence of tumor cells in vivo, as evidenced by BrdUrd
incorporation in vivo, whereas MSCs implanted without
tumors did not proliferate [32]. Hence, the increased tumor
mass observed could be related to: (a) increased number of
tumor cells; (b) increased proliferation of MSCs in tumors;
(c) combination of both. As the relative proportion of stroma
cells in these tumors has never been determined, the observed
‘‘enhancement’’ of tumor growth has to be interpreted with
caution.
Finally, MSCs have been reported to undergo transforma-
tion into malignant cells and form tumors in vivo. However,
three groups of investigators have now found that the ‘‘malig-
nant’’ MSCs were contaminated with tumor cells used for
other projects in their laboratories. Garcia-Castro and co-
workers reported initially that MSCs underwent spontaneous
transformation but recently found contamination with HT1080
sarcoma cells [53, 54]. Rosland et al. reported a similar ﬁnd-
ing [55] but found recently that their MSCs were contami-
nated with HT1080 and U-2 OS cells [15]. These ﬁndings
emphasize the importance of frequently subjecting cell lines
to DNA ﬁngerprinting, preferentially by short tandem repeat
proﬁling and suggest caution when MSCs are reported as
causing tumors or enhancing tumor growth. Importantly, after
transplantation of MSCs into over 1,000 patients, not a single
case of MSC-related tumors has been reported.
MSC Inhibition of Tumor Growth
In direct contradiction to the studies reporting that MSCs sup-
port tumor growth, other studies have shown that MSCs sup-
press tumor growth (Table 2). MSCs inhibited the growth of
rat colon carcinoma when coinjected with equal number of
MSCs and tumor cells or with 10-fold more MSCs [56]. Mac-
rophage and granulocyte inﬁltration was noted to be much
higher in tumors injected with MSCs than in tumors not
injected with MSCs, suggesting that MSCs had proinﬂamma-
tory effects in this model. In fact, MSCs alone also generated
increased engraftment of monocytes and granulocytes, which
Table 2. Studies reporting that mesenchymal stem cells inhibit tumor growth
Author Isolation Tumor model MSC:tumor cell ratio Findings Proposed mechanism
Ohlsson et al. [15] MPC1cE MSC Rat colon carcinoma
cells (H1D1)
1:1 and 10:1 in
gelatin matrix
Tumor size smaller Increased
inﬂammatory
inﬁltrate
Khakoo et al. [16] Human BMD-MSC Kaposi sarcoma 3   10
6 MSC
injected i.v.
Tumor size smaller AKT signaling
Qiao et al. [17] Human fetal skin Human hepatoma cell
line (H7402
HepG2)
1:1 coinjection Tumor size smaller Wnt signaling
Qiao et al. [18] Human fetal skin Breast cell line
(MCF-7)
1:100 coinjection Increased latency,
reduced tumor
size, and
metastasis
Wnt signaling
Zhu et al. [19] Human ASC Human myelogenous
leukemia (K562)
cell line in nude
mice
1:10 grown isolation
in vivo
Proliferation inhibited Secretion of DKK-1
Otsu et al. [20] Rat BMD-MSC Mouse B16F10
melanoma cell line
10
6 into a established
700 mm
3 tumor
Tumor size smaller Inhibition of
angiogenesis
Cousin et al. [21] Human ASC Pancreatic cancer
cells
10
3 ASCs per mm
3
of established
tumor
Tumor size smaller G1 arrest
Maestroni et al. [22] BMD-MSC Lewis lung and
melanoma (B16)
1:1 coinjected Tumor size smaller
and decreased
metastasis
Increased by
treatment of MSC
with GM-CSF
Lu et al. [23] Mouse BMD-MSC Hepatoma (H22),
lymphoma (Tac-1
and EL-4), and rat
insulinoma (INS-1)
2–4:1 i.p. into
tumor-bearing
mice
Decreased ascites
formation
Induced apoptosis
and cell cycle
arrest in G0/G1
phase
Dasari et al. [24, 25] Umbilical cord
blood-derived
Glioma (SNB19 and
U251, 4910 and
5310)
1:4 injected 7 days
later into
contralateral
hemisphere
Decreased tumor size Upregulation of
PTEN
Secchiero et al [26] BMD-MSC Non-Hodgkins
lymphoma
(SKW6.4
and BJAB)
1:10 and 1:2 injected
i.p. 4 days later
Decreased tumor
burden with
increased survival
Endothelial cell
apoptosis in vitro
Abbreviations: ASC, adipose stem cell; BMD, bone-marrow-derived; DKK1, Dickkopf-related protein-1; GM-CSF, granulocyte-macrophage
colony-stimulating factor; i.p., intraperitoneally; i.v., intravenously; MSC, mesenchymal stem cell; PTEN, phosphatase and tensin homolog.
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MSCs transplanted into a nonidentical rat strain and may
have contributed to the antitumor effect of MSCs in this
model. In a highly inﬂammatory and angiogenic Kaposi sar-
coma model, MSCs but not human umbilical vein endothelial
cells, inhibited tumor growth in the xenografts [16]. The use
of athymic nude mice in these experiments suggests that the
inhibitory effects of MSCs were not due to immunomodula-
tory effects.
Human fetal skin-derived MSCs inhibited human liver can-
cer cell lines, with reduced proliferation, colony formation, and
oncogene expression both in vitro and in vivo [17]. When these
cell lines were coinjected with the same number of MSCs, tu-
mor development was delayed and tumor size decreased.
The same fetal skin-derived MSCs inhibited growth of
MCF-7 breast cancer cells in vitro [18]. The researchers found
that treatment with conditioned media resulted in downregula-
tion of survival factors, such as b-catenin, c-Myc, and survi-
vin. This effect was mediated by an inhibitor of b-catenin sig-
naling, Dickkopf-related protein-1 (DKK-1), which is secreted
by MSCs [18]. The DKK-1 effects were suppressed in MSCs
with the use of a neutralizing antibody and small interfering
RNA, eliminating the growth inhibitory effects of MSCs.
Adipose-derived MSCs were also found to inhibit prolifer-
ation of primary leukemia cells [19]. This effect was mediated
by secreted DKK-1, which was regulated by the stem cell
transcription factor NANOG [19].
MSCs have been shown to suppress pancreatic tumors by
altering cell cycle progression. In vitro coculture with MSCs
increased rates of G1-phase arrest in pancreatic cancer cells
[21]. In vivo injection of adipose-derived stem cells into
established pancreatic cancer xenografts inhibited tumor
growth [21]. In a similar approach, bone marrow-derived
MSCs were injected into established subcutaneous melano-
mas, resulting in apoptosis and abrogation of tumor growth
[20]. When MSCs were placed in a Matrigel insert, such that
tumors were exposed to soluble factors but not in contact
with MSC, MSCs had no cytotoxic effects.
The impact of hyperthermic treatment was tested in an in
vitro study in which adipose-derived stem cells were heated
[57]. Ovarian cancer SKOV-3 cells were cultured with super-
natant from these heat-treated MSCs, resulting in decreased
cell number and viability. Cho et al. [57] proposed that the
decrease in cell number and viability was due to various
secreted factors, including angiogenin, insulin-like growth fac-
tor (IGF) binding protein 4, neurotrophin 3, and chemokine
(CAC motif) ligand (CCL) 18 [57].
MECHANISMS OF MSC-MEDIATED EFFECTS OF
TUMOR SUPPORT OR SUPPRESSION
Vascular Support
MSCs have been reported to support the tumor vasculature
directly, by differentiating into pericytes and perhaps endothe-
lial cells [58] and through indirect mechanisms, by secreting
vasculogenic growth factors [59]. Two lines of evidence sug-
gest that MSCs differentiated into pericytes. Transplanted
MSCs engraft in the perivascular niche in close contact with
the underlying endothelial cells [60]. In addition, pericytes
isolated from the stromal-vascular compartment have been
shown to contain a MSC-like population with characteristic
cell surface marker expression (CD10, CD13, and CD90) and
the capacity to differentiate into tissues of mesenchymal line-
age [61, 62]. Within mouse brain, a population of MSC-like
cells has been identiﬁed in the perivasculature [63].
MSCs also secrete various proangiogenic factors, such as
VEGF, ﬁbroblast-derived growth factor, PDGF, and stromal-
derived factor-1 (SDF-1). These cytokines promote endothe-
lial and smooth muscle migration and proliferation at the tu-
mor site, facilitating angiogenesis [64, 65].
MSC-secreted factors, such as VEGF, support blood ves-
sel growth. MSCs expressing VEGF increased microvessel
density in pancreatic xenografts [47]. However, recombinant
VEGF at the same concentration found in the MSC-condi-
tioned media did not have the same proliferative effect on
vessel growth as did the MSC-conditioned media [65], sug-
gesting that other proangiogenic cytokines are also involved.
Other growth factors implicated in MSC effects on tumor vas-
culature include hepatocyte growth factor, cyclooxygenase,
IGF-1, PDGF-a, and transforming growth factor-a1 [47].
Interestingly, expression of proangiogenic factors is increased
by growth of MSCs as spheroids as compared with growth as
monolayers [64].
In what appears to be a direct conﬂict with this data,
MSCs appear to inhibit capillary growth under certain condi-
tions. MSCs migrate in vitro toward endothelial cell-derived
capillaries in Matrigel, incorporate into these vessels, and pro-
duce reactive oxygen species, resulting in endothelial cell ap-
optosis [20]. These researchers found that an endothelial cell
to MSC ratio of 1:1 or 1:3 resulted in cytotoxicity but coin-
jection with 10% MSC resulted in no cytotoxicity. The
growth-suppressing effect of MSCs was observed in vivo in
which established melanomas injected with MSCs had
reduced tumor growth and tumors exhibited lower vascular
density [20].
Fibrovascular Network
Fibroblasts, which are the primary cell type comprising tumor
stroma, are a critical component of the tumor microenviron-
ment. Tumor ﬁbroblasts (referred to as TAFs) are derived in
part from MSCs that may be recruited regionally or from cir-
culating populations [44, 66]. After exposure to the tumor
microenvironment, MSCs acquire expression of TAF antigens,
such as a-smooth muscle actin, ﬁbroblast-speciﬁc protein,
vimentin, and SDF-1 in vivo and in vitro following coculture
with tumor cells or using tumor-conditioned media [3, 66].
The importance of TAFs in promoting tumorigenesis has
been well established in multiple tumor models [67]. TAFs
extracted from human tumors facilitate the growth of human
breast and ovarian cancers when coinjected into immunosup-
pressed mice [68]. This appears to involve multiple mecha-
nisms, including the inhibition of cancer cell apoptosis,
increased tumor cell proliferation, and promotion of angiogen-
esis. Thus, the acquisition of a TAF phenotype in MSC-
derived tumor stroma provides indirect evidence for the protu-
mor effect of MSCs.
Immunomodulatory Effects of MSCs in Tumors
MSCs are generally thought to have immunosuppressive
effects, which may be an important mechanism through which
MSCs promote tumor growth or increase incidence of tumor
formation in vivo. MSCs can directly impair the function of a
variety of immune cells, including B and T lymphocytes, den-
dritic cells, and natural killer cells [69–75]. These immuno-
suppressive qualities of MSCs have been exploited to reduce
GvHD following allogenic stem cell transplantation [76, 77].
MSCs suppress T-cell proliferation through multiple
mechanisms. IFN-c directly enhances the T-cell suppressive
effects of MSCs through upregulation of an inhibitory cell
surface marker, B7-H1 [78]. A subpopulation of MSC, identi-
ﬁed by Stro-1þ expression, has the most potently inhibitory
effects on T-cell proliferation [79].
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shown to regulate the immunomodulatory properties of MSCs
[80]. TLR respond to ‘‘danger’’ signals triggering the innate
and adaptive immune responses. MSC express TLR and acti-
vation of certain receptors can polarize MSC to switch from a
predominately immune suppressive to a proinﬂammatory phe-
notype [80]. It is possible that discrepant reports in the litera-
ture may be attributed to the activation of different TLR as a
consequence of variability in TLR expression and environ-
mental ligand expression.
The immunomodulatory effects of MSCs, if any, are not
well understood within tumors. Djouad et al. [6] reported that
the immunosuppressive action of MSCs led to a higher inci-
dence of melanoma formation in a mouse model. Evidence
for the effect of MSCs on tumor immunology also comes
from a clinical study conducted to investigate whether the
immunosuppressive qualities of MSCs could reduce the
immunologic side effects of GvHD. Cotransplantation of
MSCs has been reported to reduce the incidence of GvHD,
but delivery of MSCs was also associated with higher rates of
leukemia relapse in one study [77]. These results suggest that
MSCs may have suppressed the graft versus leukemia effect
and the graft versus host response. Alternatively, MSCs may
have directly supported leukemia progression through other
mechanisms, for example, by generating a specialized bone
marrow niche supportive of residual leukemic cells [81, 82].
Clinical studies of the potential immunosuppressive effects of
MSCs in Crohn’s disease are in progress.
Metastasis
Karnoub et al. reported that MSC-secreted CCL5 induced a
transient prometastatic effect on breast cancer cells [4].
Tumors coinjected with MSCs exhibited a twofold to seven-
fold increase in the number of breast cancer cells in the lungs
[4]. Tumor cells isolated from the lung metastasis had equal
rates of metastasis as compared with breast cancer cells taken
from the primary tumors, suggesting that the effect of MSCs
on metastasis is primarily not due to selection of a population
of cells with an increased capacity to metastasize but rather to
transient changes elicited by exposure to MSCs. Additionally,
the prometastatic effect required the MSCs to be injected to-
gether with the tumor cells and was not seen when MSCs
were injected distantly, demonstrating that the effect requires
contact or exposure to paracrine signaling from the MSCs.
Furthermore, MSCs themselves were not found in the pulmo-
nary metastasis. These experiments support a model in which
MSC-secreted factors reversibly modify tumor cells to
increase their metastatic potential. The researchers addition-
ally found that there was no increase in the number of meta-
static tumor cells seen in the murine lungs when tumor cells
were coinjected with other cells of mesenchymal lineage, sug-
gesting that the prometastatic effect is a unique quality of
MSCs. CCL5 secreted by MSCs and chemokine receptor 5
expression on breast cancer cells was found to be critical for
the prometastatic effect of MSCs in two of the four breast
cancer cell lines tested [4].
MSCs may modulate the epithelial-to-mesenchymal transi-
tion (EMT), a developmental process that is subverted by tumor
cells resulting in a more invasive phenotype [83]. In breast can-
cer, coculture with MSCs resulted in upregulation of EMT-spe-
ciﬁc markers (N-cadherin, vimentin, Twist, and Snail) and a
decrease in E-cadherin [84]. A similar effect was observed in
prostate cancer cells that were cocultured with carcinoma-asso-
ciated ﬁbroblasts [85]. We observed that MSC-secreted factors
increase mammosphere formation in normal and malignant
breast cells and that mammospheres formed in the presence of
MSC-conditioned media exhibited lower levels of E-cadherin
expression and an increase in N-cadherin expression, character-
istic of EMT [86]. This may be an additional mechanism by
which MSCs inﬂuence tumor cell metastasis.
MSCs may also modify the metastatic niche, supporting the
formation of early metastasis through vasculogenesis or growth
factor secretion. For example, Corcoran et al. [87] reported that
MSCs facilitated the entry of breast cancer cells into the bone
marrow through Tac-1 regulation of SDF-a1 and C-X-C chemo-
kine receptor type 4 (CXCR4), a G-protein couple receptor.
Secretion of Paracrine Factors
MSCs secrete a variety of growth factors that are known to inﬂu-
ence tumor proliferation, migration, and angiogenesis (Table 3).
In addition, MSCs have also been recently reported to secrete
exosomes or microparticles [94, 95]. Microparticles are lipid
vesicles that are less than 1 mm in diameter and are secreted by
cells. They may contain proteins or RNA that regulate intracellu-
lar signaling in adjacent cells [94, 95]. MSC-secreted micropar-
ticles contain microRNAs in the precursor form, which represent
a subset of microRNAs found within MSCs. MSC-secreted
microparticles may thus be one of the unappreciated mechanisms
of MSC signaling within the tumor microenvironment.
Modulating Tumor Response to Cytotoxic Therapy
Although a great deal of research has focused on the role of
MSCs as delivery vehicles for antitumor proteins or viruses,
targeting endogenous MSCs in tumors also has the potential
to be an effective therapy. Studies investigating the effects of
MSCs on response to cytotoxic therapy have demonstrated
that MSCs can protect tumor cells from chemotherapy. Inter-
actions with MSCs in bone marrow has been shown to pro-
mote survival of acute and chronic myelogenous leukemia
[82, 96–98]. Coculturing MSCs with acute myelogenous leu-
kemia cells resulted in the upregulation of antiapoptotic bcl-2
with reduced rates of apoptosis in response to cytotoxic
Table 3. Proteins reported to be secreted by MSC
IL-6 [88–91] Collagen type 1
(alpha 1 and 2 chain) [88]
IL-8 [88–91] Collagen type V
(alpha 2 chain) [88]
TGF-B [88] Collagen type VI
(alpha 1 chain) [88]
FGF-4,7,9 [91]
MCP-1 [88] Collagen type XII
(alpha 1 long isoform) [88]
Rantes [88] Fibronectin [88]
IGF binding protein
family [88, 91]
Fibronectin (type III domain) [88]
SPARC [88]
PDGF-a [92] IL-13 [89]
Hepatocyte growth
factor [90]
SDF-1 [89]
Urokinase plasminogen
activator [89]
VEGF [89]
TIMP-1 and 2 [91, 93] CCL2 [93]
Secreted frizzled
related protein-1 [92]
Dickkopf-1 [18]
IGF-1 [47] TGF-a1 [47]
Abbreviations: CCL2, chemokine (CAC motif) ligand; FGF,
ﬁbroblast growth factor; IGF-1, insulin-like growth factor; IL,
interleukin; MCP-1, monocyte chemotactic protein-1; PDGF-a,
platelet-derived growth factor-a; SPARC, secreted protein acidic
and rich in cysteine; TGF, transforming growth factor; TIMP-1,
TIMP metallopeptidase inhibitor 1; VEGF, vascular endothelial
growth factor.
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which is expressed on leukemic stem cells. Disrupting this
interaction with CXCR4 inhibitors [98] overcomes, in part,
the stroma-mediated chemotherapy resistance [82, 97].
MSCs secrete high levels of leptin, which has antiapop-
totic properties, during adipocyte differentiation [99]. MSC-
derived adipocytes decrease leukemic cell apoptosis in
response to doxorubicin through a cell contact-dependent
mechanism.
CONCLUSION
MSCs interact with tumor cells in a myriad of ways, which
have the potential to support or suppress tumor growth. Addi-
tionally, MSCs interact with their tumor-resident neighbors,
such as immune cells (macrophages and T cells) and endothe-
lial cells. Other cell types have also been shown to play roles
in modulating tumor progression, thereby potentially exacer-
bating or inhibiting the outcomes of the MSC-tumor
interactions.
The heterogeneity in MSC is likely a major factor contrib-
uting to the inconsistent reports about the effects of MSC in
tumors. The MSC used in the studies reviewed here were iso-
lated largely on the basis of plastic adherence. These MSCs
exhibited appropriate cell surface marker expression as well
as multipotency and yet these cell populations are fundamen-
tally different in critical ways. To address this concern, cell
surface markers that permit isolation of a more homogenous
population are needed. Several markers, such as NG2 [100],
have been proposed to be useful makers to identify a more
homogenous population of MSC, which could make the
results of studies such as these more readily comparable.
The studies reviewed here reported both growth promotion
and suppression for the same cell types, including adult- and
fetal-derived bone marrow, suggesting that the age of the do-
nor does not determine the effect of MSC on tumor progres-
sion. Zhu et al. [5] directly compared the effects of bone mar-
row-derived MSCs isolated from a 40-week fetus with the
effects of bone marrow-derived MSCs isolated from an adult.
The researchers found marked growth promotion from both
cell types. However, the tumors injected with adult MSCs
developed more rapidly (100% incidence of tumors by day
20) than did those injected with fetal MSCs (20%–80% tumor
incidence by day 20), suggesting that the adult MSCs had
greater tumor growth-promoting activity.
The effects of propagating cells ex vivo are also variable
and may contribute to these discrepant results. Authors have
reported growing MSC in high serum or growth factor supple-
mented media, which may alter the MSC phenotype. In addi-
tion, passage number and conﬂuence may impact MSC func-
tion. Studies using endogenously labeled lineages of stromal
cells will eliminate these concerns and will help clarify the
effects of MSC or MSC-like cell in vivo. Finally, it is not
known what proportion of ‘‘MSC’’ cell lines are contaminated
with tumor cells, such as reported contamination with osteo-
sarcoma and glioma cells used in the same laboratories [15].
Fingerprinting of all cell lines used should therefore be de
rigueur and will help reducing confusion regarding biological
properties of MSC.
In vivo tumor models vary widely and may also account
for some of the differences in the ﬁndings of these studies.
Tumor immunity, hypoxia, angiogenesis, and cytokine secre-
tion are all highly variable in the models described in these
studies. However, MCF-7 breast cells and B16 melanoma
cells were reported by different investigators to be both pro-
moted and suppressed by MSC delivery, suggesting that the
tumor model is not the only factor accounting for the dispar-
ate ﬁndings.
The dose of MSCs delivered has been proposed to be a
determinate of MSC effects on tumor growth. In general,
studies that reported growth promotion tended to use a higher
MSC to tumor cell ratio. However, low percentages of MSCs,
such as the 10% used by Yu et al. [9], promoted subcutaneous
growth in a lung and glioma cell line. These researchers [49]
reported that coinjection of a higher percentage of MSCs fur-
ther augmented tumor growth, suggesting that, in the right
conditions, MSCs may impact tumor growth in a dose-de-
pendent manner.
The timing at which MSCs are introduced into the tumor
microenvironment may be an important consideration. All
three of the studies that introduced MSCs into established
tumors reported tumor growth inhibition [21, 20, 23]. Three
other studies reporting growth inhibition involved modiﬁca-
tions, such as implantation into a gelatin matrix or intrave-
nous delivery of MSCs, which may have minimized the direct
contact of MSCs during tumor initiation. By contrast, all of
the studies reporting growth promotion mixed MSCs with tu-
mor cells and coinjected the cells. The presence of MSCs dur-
ing early tumor growth may facilitate processes, such as
angiogenesis, which are required for tumor initiation. This hy-
pothesis is consistent with the studies investigating MSC
interactions with the vasculature. Coinjection of MSCs with
pancreatic cancer cells resulted in increased vessel density,
which required MSC-derived VEGF expression [47]. By con-
trast, MSCs induced endothelial cell apoptosis in established
Matrigel capillaries, and delivery of MSCs into established
melanoma xenografts abrogated tumor growth.
Finally, patient-to-patient variability in MSC isolates may
also contribute to the conﬂicting data reported in the litera-
ture. It is possible that due to genetic, epigenetic, or environ-
mental effects, MSCs may have different effects on the tumor
microenvironment and could conceivably contribute to an
individual’s cancer risk. To address this, studies of MSCs
from patients predisposed to cancer because of somatic muta-
tions, such as BRCA, or environmental exposures, such as
cigarette smoking, may be helpful to determine if patient-to-
patient variability exists.
In summary, no simple paradigm can account for the con-
ﬂicting ﬁndings in the studies of MSCs. Understanding the
nuances of the interaction between MSCs and cancer cells is
especially critical given the therapeutic potential of MSCs.
The possibility of MSCs promoting tumor growth and metas-
tasis raises concerns about the safety of their use as clinical
tools. No evidence of tumor formation has been reported in
over 1,000 patients treated with MSC for a variety of indica-
tions, so far. MSCs that have been engineered to express anti-
tumor cytokines have potent antitumor effects, suggesting that
perhaps putative tumor-promoting effects of MSCs can be
overcome by manipulating cytokine expression. Additionally,
MSCs could also be engineered to express a suicide gene so
that MSCs delivered systemically would migrate into tumors,
express an antitumor protein, and then be terminated with the
delivery of an agent, such as gancyclovir, resulting in selec-
tive termination of the exogenously delivered MSCs. Further-
more, therapeutic strategies aimed at disrupting tumor-pro-
moting effects of MSCs opens the door to a novel therapeutic
strategy, but this would need to be properly timed to prevent
disruption of a growth-suppressive MSC-tumor cell interac-
tion. This review highlights the critical need for studies
designed to explicitly test the hypothesis that tissue source,
individual donor variability, timing of MSC injection, or
expression of critical receptors such as TLR, determine the
16 Do MSCs Support or Suppress Tumor Growth?effect of MSC on tumor progression. Only systematic analysis
of the role of these and other factors will resolve this impor-
tant issue.
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